Melanoma trials recruiting in Virginia

All Melanoma trials nationally

Cities in Virginia

Recruiting trials in Virginia

• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
  NCT06961006 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
  NCT06022029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
  NCT07584226 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
  NCT05746897 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
  NCT07317505 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Charlottesville, Fairfax, Norfolk, Richmond
• A Study of BI 3810944 in Patients With Advanced Cancer
  NCT07224425 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Charlottesville
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
  NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Charlottesville
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
  NCT06090266 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
  NCT06805825 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
  NCT07749586 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
  NCT04913285 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
  NCT07115043 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
  NCT06326411 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
  NCT06418204 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fishersville, Fredericksburg, Lynchburg, Richmond
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
  NCT05136196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Alexandria, Fairfax, Falls Church, Lynchburg
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Virginia: Chesapeake, Fishersville, Mechanicsville, Midlothian
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
  NCT06953089 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Virginia Beach
• Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
  NCT03567889 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Richmond
• Excision of Lymph Node Trial (EXCILYNT) (Mel69)
  NCT05839912 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Charlottesville
• FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
  NCT06472661 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Charlottesville
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Charlottesville, Richmond
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Charlottesville, Newport News, Richmond, Roanoke
• Neoadjuvant Darovasertib in Primary Uveal Melanoma
  NCT07015190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fishersville
• Phase 1 Study of PF-08046033 in Advanced Solid Tumors
  NCT07519655 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
  NCT05280314 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Richmond
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female) · Virginia: Charlottesville, Falls Church, Norfolk, Portsmouth
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Richmond
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Virginia: Charlottesville
• Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
  NCT06425926 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Richmond
• Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
  NCT07287917 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  NCT06585410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Richmond
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
  NCT06332755 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
  NCT05727904 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Virginia: Richmond
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Fairfax
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Virginia: Charlottesville, Richmond